Zöldhályog (glaukóma): ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• VEGF 1
• NRF2 0
• PI3K 0
• STAT3 0
• AMPK 0
• MAPK 0
• AKT 0
• GLP-1 1
• NLRP3 0
• STING 0
• TNF 0
• IL-1 0
• JAK 0
• MMP-9 1
• PPAR 0
• SIRT1 0
• TP53 0
• ACE2 0
• GPX4 0
• IL-6 1
• mTOR 0
• YAP 0
• APOE 0
• BDNF 0
• CD38 0
• CGRP 0
• COX-2 0
• ERK 0
• GIP 0
• HSP90 0
• IL-17 0
• MEK 0
• MYCN 0
• NF1 0
• NMDA 0
• PDGFR 0
• RANKL 0
• RB1 0
• TIM-3 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Next-generation therapeutics for vascular diseases (TIE2gether)

  Helsingin Yliopisto· Helsinki, Finnország· EU contribution 4 273 568 EUR· until 2031. jan.· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Tailored lipid nanoparticles for iontophoretic ocular drug delivery. (ODiN)

  Universita Degli Studi di Parma· Parma, Olaszország· EU contribution 193 643 EUR· until 2029. jan.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Peptidomimetic therapy to promote central Nervous System repair (POPEYE)

  Institut National de la Sante Et de la Recherche Medicale· Paris, Franciaország· EU contribution 150 000 EUR· until 2027. jún.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Pharmacological and gene therapy targeting of NMNAT2 for neuroprotection in glaucoma (TARGET-NMNAT2)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 2 261 875 EUR· until 2030. szept.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Nanoparticle-mediated ocular delivery of novel NAD-boosting small molecules for ophthalmic disease. (NanoNAD)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 252 180 EUR· until 2027. márc.

5 of 8 running projects, newest first. Listed amounts together: 14,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 8
• Organoids 2
• Mendelian Randomization Analysis 24
• CRISPR-Cas Systems 3
• Gene Expression Profiling 15
• Sequence Analysis, RNA 1
• Exome Sequencing 16
• Proteomics 21
• Metabolomics 11
• Mass Spectrometry 4
• Flow Cytometry 7
• Immunohistochemistry 17
• Magnetic Resonance Imaging 22
• Machine Learning 27
• Deep Learning 35
• Cohort Studies 24
• Genome-Wide Association Study 29

• Comparative proteomics of human anterior lens capsules reveals ATP6V1A-associated lysosomal dysregulation in age-related cataract with primary angle-closure glaucoma.

  J Transl Med, 2026. szept.

• Canine Tear Proteomics: A New Frontier in Veterinary Ophthalmology.

  Vet Ophthalmol, 2026. szept.

• Sex-Dependent Responses in the Retina Proteome to Ocular Hypertension in a Mouse Model of Glaucoma.

  Int J Mol Sci, 2026. aug.

• Proteomic Analyses of Early Versus Advanced Primary Open-Angle Glaucoma Uncover Biochemical Signatures Associated With Disease Staging.

  Mol Cell Proteomics, 2026. júl.

• Proteomic Profile Analysis of Plasma and Aqueous Humor from Glaucoma and Nonglaucomatous Patients.

  J Ocul Pharmacol Ther, 2026. júl.

• Transcending genome-wide association studies to create useful multi-omic views of glaucoma.

  Prog Retin Eye Res, 2026. júl.

• Integrative Multi-Omics Analysis Prioritizes Candidate Therapeutic Targets for Primary Open-Angle Glaucoma.

  Int J Mol Sci, 2026. máj.

• Multi-omics panorama of glaucoma: Pathogenesis, biomarkers, and novel therapeutic strategies.

  Surv Ophthalmol, 2026. máj.

• Integrated plasma proteomics and metabolomics reveal immunometabolic pathways and predictive signatures for age-related eye diseases.

  Metabolism, 2026. ápr.

• Advances in the application of metal-organic frameworks in ophthalmology.

  Biomater Sci, 2026. ápr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.